Feed XENE
XE

Xenon Pharmaceuticals XENE NASDAQ · Healthcare · Canada

$37.56 -0.50% -$0.19

Summary

43 / 100 · Bulios Score

What speaks for it

  • It holds more cash than debt: $82.6M against $6.01M.
  • The price moves less than the market (beta 0.60).

What to watch

  • Revenue fell by 7.4% a year over the last 3 years.
  • Analysts expect revenue to fall by 79% this fiscal year.
  • It passes only 2 of the 9 points of the Piotroski financial health test.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Fairly priced
Valuation in detail

Is it growing?

It is shrinking

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue fell by 25% a year over 5 years. Over the last 3 years it fell by 7.4% a year. For the next fiscal year analysts expect revenue to fall by 79%.

Growth in detail

Does it make money?

Over the last 12 months it made a loss of $428.7M.

Profitability in detail

Is it financially healthy?

Yes

Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $68.63 is 83% above today's price. 95% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2022

By product

By region

The company reports no revenue by region.

License and Service brings in 100% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy